Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-894 · 2 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | ABT-894 1 mg BID |
| B | EXPERIMENTAL | ABT-894 2 mg BID |
| C | EXPERIMENTAL | ABT-894 4 mg BID |
| D | PLACEBO_COMPARATOR | - |
| E | ACTIVE_COMPARATOR | Duloxetine 60 mg QD |
| Name | Type | Description |
|---|---|---|
| ABT-894 | DRUG | 6 mg BID tablets, 8 weeks of treatment |
| placebo | DRUG | BID tablets, 8 weeks of treatment |
| Duloxetine | DRUG | Duloxetine 60 mg QD throughout treatment period |
Inclusion Criteria: * Males and females, age 18 to 75 * If female, must be of non-childbearing potential or practicing birth control * Has diabetes mellitus (Type 1 or 2) and a diagnosis of painful distal symmetric diabetic polyneuropathy * Has had pain from distal symmetric diabetic polyneuropathy...
ABT-894 is an investigational small molecule being developed for diabetic neuropathic pain and diabetic neuralgia. It is a neurology therapeutic that has been studied in Phase 2 clinical trials for these painful diabetic neuropathy conditions.
ABT-894 is a small molecule therapeutic developed for neurology indications. Its specific molecular target has not been disclosed in available clinical trial information, so its precise mechanism of action is not publicly detailed.
ABT-894 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV.
ABT-894 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, with no active trials currently listed.
ABT-894 has completed two Phase 2 trials. NCT00507936 enrolled 280 participants with diabetic neuropathic pain across multiple countries. NCT00548925 enrolled 124 participants with diabetic neuropathic pain. Both were randomized, double-blind, placebo-controlled studies.
ABT-894 is the primary name used in clinical trial registrations for this investigational compound. No alternative names have been associated with this drug in the available clinical trial data.